Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma

Swiss Medical Weekly

Volumn 136, Issue 25-26, 2006, Pages 400-403

  Trojan, Andreas ^a   Tinguely, Marianne ^c   Vallet, Sonia ^b   Seifert, Burkhardt ^c   Jenni, Bettina ^c   Zippelius, Alfred ^d   Witzens Harig, Mathias ^e   Mechtersheimer, Gunhild ^e   Ho, Anthony D ^e   Goldschmidt, Hartmut ^e   Jäger, Dirk ^e   Boccadoro, Mario ^b   Ladetto, Marco ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF ZURICH   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cyclooxygenase 2 (COX 2); Immunohistochemistry; Multiple myeloma; Prognosis

Indexed keywords

CYCLOOXYGENASE 2; PROSTAGLANDIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PATHOGENESIS; PROPORTIONAL HAZARDS MODEL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; STEM CELL TRANSPLANTATION;

EID: 33745769736     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1 alpha and MIP-1 beta in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195-202.
2. Ladetto M, Vallet S, Trojan A, Dell'Aquila M, Monitillo L, Rosato R, et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 2005;105:4784-91.
3. Hideshima T, Richardson P, Anderson KC. Novel therapeutic approaches for multiple myeloma. Immunol Rev 2003;194:164-76.
4. Hazar B, Ergin M, Seyrek E, et al. Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leuk Lymphoma 2004;45:1395-9.
5. Haller DG. COX-2 inhibitors in oncology. Semin Oncol 2003;30(4 Suppl 12):2-8.
6. Hus M, Dmoszyñska A, Kocki J, Hus I, Jawniak D, Adamczyk-Cioch M, Grzasko N. Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma. Leukemia 2005;19:1497-9.
7. Zhong H, Willard M, Simons J. NS398 reduces hypoxia-inducible factor (HIF)-1alpha and HIF-1 activity: multiple-level effects involving cyclooxygenase-2 dependent and independent mechanisms. Int J Cancer 2004;112:585-95.
8. Liu H, Wang J, Epner EM. Cyclin D1 activation in B-cell malignancy: association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences. Blood 2004;104:2505-13.
9. Giles FJ, Kantarjian HM, Bekele BN, Cortes JE, Faderl S, Thomas DA, et al. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol 2002;119:38-45.
10. Prince MH, Mileshkin L, Roberzts A, et al. A Multicenter Phase II Trial of Thalidomide and Celecoxib for Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Research 2005;11:5504-14.